Search results for: 'software energy ai data analysis'

By 2023, biologics constituted 44% of the therapeutic pipeline, with antibodies and recombinant proteins as leading categories. Nevertheless, advancements in these fields decelerated, with most of the expansion happening in heterologous cell treatments, synthetic nucleic acids, and viruses. The global biologics pipeline will shift toward more compl...

24 Oct 2018  |  North America  |  Market Research

Growth Opportunities in the Global Cell Therapy Market, Forecast to 2025

A Robust Product Pipeline Creating Opportunities for Ground-breaking Combination Therapies is Set to Revolutionize the Global Cell Therapy Market

Infographics

×

Key Issues Addressed

The global pharmaceuticals industry is continuously evolving to meet the requirements of a changing disease landscape. With the increasing prevalence of chronic infectious diseases and cancer, market needs are shifting from traditional small molecules to novel large molecule therapies, with cell therapies dominating the space. This study presents a...

The Frost & Sullivan research service discusses the cell and gene therapy (CGT) market and highlights some key roadblocks in viral vector manufacturing. While many CGT candidates exist in the pipeline, there is a huge capacity deficit that the industry is collaboratively trying to address. Scalability, costs, reproducibility, and overall process ef...

13 Sep 2021  |  North America  |  Market Research

Global Small Molecule Contract Development and Manufacturing Organization (CDMO) Growth Opportunities

Emerging Pharmaceuticals and Highly Potent Complex Molecules Creating Future Growth Potential

Infographics

×

This study presents Frost & Sullivan’s overall market and segment-wise revenue forecasts of the global small molecule contract development and manufacturing organization (CDMO) industry. It highlights key growth opportunities for small molecule CDMOs based on the main evolution in their business models and strategic approaches as well as those of p...

17 Jun 2021  |  North America  |  Market Research

Global Biologics Contract Development and Manufacturing Organizations Growth Opportunities

Asset Co-Development with Clinical-stage Biopharmaceutical Companies and Disruptive Technologies Present Future Growth Potential

Infographics

×

This study presents Frost & Sullivans overall market and segment-wise revenue forecasts of the global biologics contract development and manufacturing organizations (bio-CDMO) market. It also highlights key growth opportunities for bio-CDMO market participants based on the main evolution in their business models and strategic approaches, as well as...

As cell and gene therapy (CGT) moves from ultra-rare indications to more common indications, manufacturing capabilities will have to expand to support the commercial requirements of these diseases. Contract research organizations (CROs) can play a critical role in long-term genetic analysis and monitor safety and efficacy up to 15 years after treat...

15 Oct 2024  |  Global  |  Technology Research

Emerging Non-opioid Treatments for Pain Management

Advances in Non-opioid Therapies for Neuropathic, Migraine, and Cancer Pain Management Unlock New Growth Opportunities

Infographics

×

The analysis explores cutting-edge advancements in non-opioid medications by delving into their mechanisms of action at a molecular scale, scrutinizing results from current clinical research initiatives, and appraising preparedness for and plausibility of regulatory approval. The considerations aim to highlight how these treatments may offer viable...

Frost & Sullivan provides comprehensive insights into the global biologics contract development and manufacturing organization (bio-CDMO) market, including emerging trends, growth opportunities, and profiles of leading bio-CDMOs and their business model evolution. The growth of next-generation biologics and personalized therapies and the emergence ...

11 Nov 2022  |  North America  |  Market Research

Global Contract Research Organization (CRO) Growth Opportunities

Strong Competitive Intensity is Mandating a Greater Industry Convergence Resulting in a Strong Market Growth

Infographics

×

Key Issues Addressed

The COVID-19 pandemic led to a sudden surge in R&D activities across the world. Both small and large pharmaceutical and biotech companies were engaged in tremendous efforts to either develop new molecules or repurpose existing therapies as potential drugs for COVID-19 treatment. The trend is likely to continue with small-to-medium-segment and e...